Survival of non-seminomatous germ cell cancer patients according to the IGCC classification: An update based on meta-analysis

Dijk, M. R. van; Steyerberg, Ewout W.; Habbema, J. Dik F.

doi:10.1016/j.ejca.2005.08.043

Cited by 106 publications

(43 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As our patient quickly progressed to respiratory failure and, as a result, we were not able to administer the recommended chemotherapy. However, the IGCCCG reported that the fiveyear overall survival rate for patients with nonseminomatous germ cell tumors with a poor-prognosis was 48%, but it was more recently reported at 71% (15). As such, there has been a large increase in survival for patients with a poor prognosis.…”

Section: Discussionmentioning

confidence: 99%

Pulmonary Metastatic Choriocarcinoma from a Burned-out Testicular Tumor

et al. 2016

View full text Add to dashboard Cite

A 54-year-old man was referred to our hospital because of progressive dyspnea. Chest computed tomography showed multiple nodular shadows with a peripheral ground-glass halo. His clinical condition continued to deteriorate with the development of progressive respiratory failure requiring mechanical ventilation. A histological examination of a transbronchial lung biopsy revealed choriocarcinoma. The patient died within nine days of admission. A histological examination of the right testis during an autopsy revealed a burned-out testicular tumor consisting of a teratoma and a fibrous scar. We herein report a rare case of pulmonary multiple metastatic choriocarcinoma originating from a burned-out testicular tumor.

show abstract

Section: Discussionmentioning

confidence: 99%

Pulmonary Metastatic Choriocarcinoma from a Burned-out Testicular Tumor

et al. 2016

View full text Add to dashboard Cite

show abstract

“…2,4 van Dijk et al carried out a meta-analysis based on 1775 cases of NSGCT treated after 1987, and estimated the 5-year OS of poor-prognosis cases as 71%. 5 Because of such progress in treatment outcomes, several investigators have proposed a new model to identify a high-risk group (so-called "very poor" cases) among poor-progno-sis cases. [6][7][8] Although such a new pretreatment prognostic classification has not been established, it is notable that a mediastinal primary site is the most powerful indicator for a poor prognosis in those analyses.…”

Section: Introductionmentioning

confidence: 99%

Identification of a subgroup with worse prognosis among patients with poor‐risk testicular germ cell tumor

et al. 2015

View full text Add to dashboard Cite

Results: The median follow-up period of all patients was 57 months. A total of 50 patients (43%) were classified as having intermediate prognosis, and 67 patients (57%) as poor prognosis according to the International Germ Cell Cancer Collaborative Group classification. As first-line chemotherapy, 92 patients (79%) received bleomycin, etoposide and cisplatin. Of all patients, 74 patients (63%) received second-line chemotherapy. The most commonly used second-line chemotherapy regimens were a combination of taxanes, ifosfamide and platinum in 49 cases (66%). Overall, 33 patients (28%) received third-line chemotherapy. A total of 88 patients (75%) underwent post-chemotherapy surgery. The 5-year overall survival for intermediate (n = 50) and poor prognosis (n = 67) was 89% and 83% (P = 0.21), respectively. In poor prognosis patients, patients with two or more risk factors (any of high lactic dehydrogenase, alpha-fetoprotein and human chorionic gonadotropin levels, and presence of non-pulmonary visceral metastases) had significantly worse survival than those with only one risk factor (71% and 91%, respectively, P = 0.01). Conclusions:The 5-year overall survivals of poor-prognosis testicular nonseminomatous germ cell tumor patients reached 83%. Further stratification of poorprognosis patients based on a number of risk factors has the potential to further identify those with poorer prognosis.

show abstract

“…In addition, to assess renal function by the estimated glomerular filtration rate (eGFR), detection and management of factors causing progression of CKD, such as hypertension and proteinuria, are recommended for CKD patients and those with a high risk for CKD. 3 The findings of this study 2 suggest that urologists and oncologists should consider this matter in follow up for testicular cancer patients after chemotherapy. The currently used equation for eGFR tends to underestimate GFR and potentially misclassify patients with measured GFR >60 mL/min/1.73 m 2 into CKD stage 3.…”

Section: Conflict Of Interestmentioning

confidence: 95%

“…1 Furthermore, in the past decade, there has been a clear trend toward improvement of survival for all risk groups; in particular, there has been a large improvement in survival rates for patients with a poor prognosis. 2 Therefore, the assessment of long-term morbidity is important when considering the life expectancy of this group of young men. 3 The morbidities include secondary malignant neoplasms, neuropathy, gonadal dysfunction, cardiovascular disease and nephrotoxicity.…”

Section: Introductionmentioning

confidence: 99%

Risk factors for chronic kidney disease after chemotherapy for testicular cancer

et al. 2012

View full text Add to dashboard Cite

Abbreviations & Acronyms BMI = body mass index CDDP = cisplatin CI = confidence interval CKD = chronic kidney disease eGFR = estimated glomerular filtration rate GFR = glomerular filtration rate IGCC = International Germ Cell Consensus IGCCCG = International Germ Cell Consensus Collaborative Group RPLN = retroperitoneal lymph node RPLND = retroperitoneal lymph node dissection sCR = serum creatinine Objective: To elucidate the patterns of and risk factors for deterioration of renal function after chemotherapy in metastatic testicular cancer survivors using the estimated glomerular filtration rate. Methods: A total of 96 patients who were treated with cisplatin-based chemotherapy for metastatic testicular cancer between January 1981 and December 2010 were enrolled in this study. The estimated glomerular filtration rate was based on the serum creatinine concentration using the formula of the Japanese Society of Nephrology. Risk factors for chronic kidney disease were examined by multivariate logistic-regression analysis. Results:The median follow-up period was 70 months (range 15-342). The median pretreatment estimated glomerular filtration rate was 98 mL/min/1.73 m 2 (range 44-216), and it gradually decreased for 1 year after the end of chemotherapy, although there was no significant change in estimated glomerular filtration rate beyond 1 year. One year after chemotherapy, 22 of 96 patients (23%) showed chronic kidney disease (less than 60 mL/min/1.73 m 2 estimated glomerular filtration rate). The multivariate analysis showed that the patients with mild renal damage (estimated glomerular filtration rate 60-89 mL/min/1.73 m 2 ) and elevated blood pressure (higher than 130/ 80 mmHg) before treatment had a significant risk with odds ratios of 2.63 (95% confidence interval 1.09-6.73) and 4.22 (95% confidence interval 1.45-12.6), respectively. Conclusions: Close monitoring of renal function is important for at least 1 year after chemotherapy for testicular cancer, especially in patients having elevated blood pressure and/or mild renal damage before chemotherapy.

show abstract

Survival of non-seminomatous germ cell cancer patients according to the IGCC classification: An update based on meta-analysis

Cited by 106 publications

References 25 publications

Pulmonary Metastatic Choriocarcinoma from a Burned-out Testicular Tumor

Pulmonary Metastatic Choriocarcinoma from a Burned-out Testicular Tumor

Identification of a subgroup with worse prognosis among patients with poor‐risk testicular germ cell tumor

Risk factors for chronic kidney disease after chemotherapy for testicular cancer

Contact Info

Product

Resources

About